Published in

American Society of Hematology, Blood, 21(125), p. 3357-3359, 2015

DOI: 10.1182/blood-2015-03-633156

Links

Tools

Export citation

Search in Google Scholar

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma

Journal article published in 2015 by Chan Yoon Cheah ORCID, Loretta J. Nastoupil ORCID, Sattva S. Neelapu, Sheryl G. Forbes, Yasuhiro Oki, Nathan H. Fowler
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO